Chronic Myeloid Leukemia Treatments
This is a sourced subject-directory page. Its presence does not mean a factual answer has been researched, or that the subject is a proven knowledge gap.
Scope of this subject
This cluster of papers focuses on the efficacy and resistance of various tyrosine kinase inhibitors, such as Imatinib, Dasatinib, and Nilotinib, in the treatment of Chronic Myeloid Leukemia (CML). The papers discuss molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and long-term outcomes of different targeted therapies.
OpenAlex generated this cluster description with an LLM. It describes research grouping, not verified findings.
Follow the subject hierarchy
Research vocabulary
chronic myeloid leukemia; imatinib; BCR-ABL; Philadelphia chromosome; imatinib resistance; dasatinib; nilotinib; blast crisis; chronic phase; BCR-ABL1; BCR-ABL fusion gene; chronic phase CML; tyrosine kinase inhibitor resistance; T315I mutation; molecular response; major molecular response; imatinib mesylate; cytogenetic response; complete cytogenetic response; accelerated phase; BCR-ABL tyrosine kinase inhibitors; ponatinib; treatment-free remission; Philadelphia chromosome-positive leukemia; bosutinib
Current OpenAlex keyword associations; absence of a keyword does not establish absent knowledge.
Find the underlying research
OpenAlex topic record · Works associated with this topic
These external lists help locate papers. Assess the paper, date, method and limitations before using it as evidence. This service does not fetch submitted URLs.
Local answer status
No owner-reviewed answer has been published for this exact subject page. This is a gap in this collection; it does not establish that the answer is unavailable elsewhere.
Numeric address and provenance
Morton address: 36240765604768170 · morton4x16-v1
Coordinates: (4, 27, 2720, 11215). The address interleaves categorical identifier bits. Nearby addresses are not guaranteed to describe semantically similar subjects.
Structured subject record · Markdown · Source snapshots and licenses
What could you not find?
Submit the specific question you still need answered. This creates a private research request for owner review; it does not declare a scientific discovery or automatically generate an answer.